Skip to main content
Premium Trial:

Request an Annual Quote

Ventana to Develop CDx for MedImmune NSCLC Drug

NEW YORK (GenomeWeb) – Ventana today said that it is collaborating with MedImmune to develop a companion diagnostic for a drug MedImmune is developing for non-small cell lung cancer.

The companion diagnostic will be an immunohistochemistry assay that aims to identify patients who express programmed cell death ligand 1. MedImmune is developing an anti-PD-L1 therapy dubbed MEDI4736, which is currently in clinical studies. The drug firm will use the Ventana assay in that study.

Ventana, which is part of the Roche Group, said the assay has been validated for use on its Benchmark series of advanced staining instruments. It added that testing for the MedImmune trial is being carried out at Ventana's companion diagnostics CAP/CLIA lab in Tucson, Ariz., and select testing sites.

"Cancer immunotherapy is a promising area that may provide long lasting benefit not achieved with other treatment approaches," Doug Ward, VP and lifecycle leader for the Ventana Companion Diagnostics business unit, said in a statement. "This collaboration is another strong example of the importance of companion diagnostics and their role in supporting the use of novel immunotherapies to target human malignancies."

Financial and other terms of the agreement were not disclosed.

The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.